Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy

Hue, Jonathan J.; Sugumar, Kavin; Markt, Sarah C.; Hardacre, Jeffrey M.; Ammori, John B.; Rothermel, Luke D.; Winter, Jordan M.; Ocuin, Lee M.

doi:10.1016/j.surg.2020.12.003

Cited by 22 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, pancreatic cancer shows broad tolerance to chemoradiotherapy and insensitivity to immunotherapy, resulting in poor therapeutic effect and poor prognosis. [20][21][22] It is of great significance for us to explore new biomarkers for early diagnosis of pancreatic cancer. [23] Prognostic biomarkers are used to detect disease recurrence or progression in patients with a related disease or medical condition, whether these markers are observed by visual inspection of the viscera or, more recently, by histopathological or genomic characterization.…”

Section: Discussionmentioning

confidence: 99%

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma

Luo,

Qiao,

et al. 2024

Medicine

View full text Add to dashboard Cite

Pancreatic adenocarcinoma is the most common malignant tumor of the digestive system and is called the “king of cancer” because it has been labeled with high malignancy, rapid progression, poor survival, and poor prognosis. Previously, it was reported that the basic leucine zipper and W2 domains 1 (BZW1) is involved in the progression of many tumors. However, its research in digestive system tumors such as pancreatic cancer is rarely studied. To explore potential biomarkers related to survival and prognosis of pancreatic cancer and provide a new targeted therapy for it. We first analyzed the mRNA and protein expression of BZW1 in pancreatic cancer. We then explored the correlation of BZW1 with survival prognosis and immune infiltration in pancreatic cancer patients. Finally, we explored BZW1-related gene enrichment analysis, including protein-protein interaction networks, gene ontology functional enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The mRNA and protein expression of the BZW1 gene in pancreatic cancer tissues were higher than those in adjacent normal tissues, and pancreatic cancer patients with high BZW1 expression had a poor prognosis. In addition, the expression of BZW1 was positively or negatively correlated with different immune cells of pancreatic cancer, such as CD4 + T lymphocytes, CD8 + T lymphocytes, B cells, macrophages, neutrophils, etc. Correlation enrichment analysis showed that we obtained 50 available experimentally determined BZW1-binding proteins and 100 targeted genes related to BZW1, and the intersection genes were eukaryotic translation termination factor 1 and Guanine nucleotide binding protein, alpha inhibiting activity polypeptide 3. Moreover, there was a positive correlation between BZW1 and eukaryotic translation termination factor 1 and Guanine nucleotide binding protein, alpha inhibiting activity polypeptide 3 genes in pancreatic cancer. Gene ontology enrichment analysis showed BZW1 was mainly related to biological processes such as “mRNA processing,” “RNA splicing,” “regulation of translational initiation,” and “activation of innate immune response.” The results of Kyoto Encyclopedia of Genes and Genomes pathway analysis further indicated that BZW1 may be involved in pancreatic carcinogenesis through the “spliceosome” and “ribosome.” The BZW1 gene may be a potential immunotherapy target and a promising prognostic marker for pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma

Luo,

Qiao,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Realistic, honest discussions with patients and their families regarding operative risks and alternatives should be undertaken. In addition, given the well-published associations between institutional pancreatectomy volume and postoperative outcomes, 47,48 it may be best practice for elderly patients with NF-PanNENs to be referred to high-volume hepatopancreatobiliary centers of excellence. Low-volume facilities and surgeons should exercise caution if considering operative management.…”

Section: Discussionmentioning

confidence: 99%

Assessing the Role of Operative Intervention in Elderly Patients With Nonfunctional Pancreatic Neuroendocrine Neoplasms

Hue¹,

Sugumar²,

Mohamed

et al. 2022

Pancreas

Self Cite

View full text Add to dashboard Cite

Objectives: Resection of locoregional pancreatic neuroendocrine neoplasms (PanNENs) is typically recommended, but there is a paucity of data on the management of elderly patients. Methods:The National Cancer Database (2004Database ( -2016 was queried for patients 80 years or older with localized PanNENs. Patients were grouped as nonoperative or operative management. Postoperative outcomes and survival were compared.Results: In total, 591 patients were included: 202 underwent resection, and 389 did not. Increasing age and pancreatic head tumors were associated with lower likelihood of resection. The overall 90-day mortality rate was 6.4%, which was higher for pancreatoduodenectomy than distal pancreatectomy (13.6% vs 5.1%, respectively). Operatively managed patients had longer median survival (80.8 vs 45.0 months, P < 0.001), and this association was independent of tumor location. On multivariable Cox regression, resection remained associated with longer survival (hazard ratio, 0.69; 95% confidence interval, 0.50-0.95). Among operatively managed patients, age and tumor location were not associated with survival; however, greater comorbidity and high-risk tumor-specific features were associated with worse survival.Conclusions: Resection of nonfunctional PanNENs in elderly patients is associated with improved survival compared with nonoperative management. Resection could be considered in appropriate operative candidates, regardless of tumor location, but the perioperative mortality rate must be considered.

show abstract

“…At the same time, it shows extensive tolerance to radiotherapy and chemotherapy. It is not sensitive to immunotherapy, resulting in poor treatment e ects, so the prognosis is poor, and the 5year survival rate is only 10% [7][8][9][10]. In addition to imaging methods such as CT and MRI, tumor markers such as CEA and CA199 are also commonly used in diagnosing pancreatic cancer [11,12].…”

Section: Introductionmentioning

confidence: 99%

Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients

Lan

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Based on TCGA, GTEx, and TIMER databases and various bioinformatics analysis methods, the potential biological roles of cuprotosis-related genes in pancreatic cancer were deeply explored, and a predictive model for pancreatic cancer patients was constructed. We downloaded the RNA-Seq data and clinicopathological and predictive data of 179 pancreatic cancer tissues and 332 adjacent normal tissues from TCGA and GTEx databases. The differential expression of cuprotosis-related genes in pancreatic cancer tissue and adjacent normal tissue was analyzed, and the LASSO regression algorithm was used to construct a prediction model and verify the validity of the model prediction. Based on the LASSO regression algorithm, a predictive model composed of three genes LIPT1, LIAS, and DLAT was screened. The corresponding survival curves showed that the constructed prediction model could significantly distinguish the prognosis of pancreatic cancer patients, and the prognosis of patients in the high-risk group was worse ( P = 0.00557). The ROC curve showed that the area under the curve of the predictive model for predicting the 4-, 5-, and 6-year survival rates in pancreatic cancer was 0.816, 0.836, and 0.956, respectively. The AUC value of this risk model was significantly higher than 0.7, which could more accurately predict the prognosis of pancreatic cancer patients. This study determined a risk-scoring model of cuprotosis-related genes, which can provide an essential basis for judging the prognosis of pancreatic cancer patients.

show abstract

Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy

Cited by 22 publications

References 45 publications

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma

Assessing the Role of Operative Intervention in Elderly Patients With Nonfunctional Pancreatic Neuroendocrine Neoplasms

Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients

Contact Info

Product

Resources

About